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Gut-brain hormones such as ghrelin have recently been suggested to have a role in reward
regulation. Ghrelin was traditionally known to regulate food intake and body weight homo-
eostasis. In addition, recent work has pin-pointed that this peptide has a novel role in drug-
induced reward, including morphine-induced increase in the extracellular levels of accumbal
dopamine in rats. Herein the effect of the ghrelin receptor (GHS-R1A) antagonist, JMV2959, on
morphine-induced activation of the mesolimbic dopamine system was investigated in mice. In
addition, the effects of JMV2959 administration on opioid peptide levels in reward related areas
were investigated. In the present series of experiment we showed that peripheral JMV2959
administration, at a dose with no effect per se, attenuates the ability of morphine to cause
locomotor stimulation, increase the extracellular levels of accumbal dopamine and to condition
a place preference in mice. JMV2959 administration signiﬁcantly increased tissue levels of Met-
enkephalin-Arg6Phe7 in the ventral tegmental area, dynorphin B in hippocampus and Leu-
enkephalin-Arg6 in striatum. We therefore hypothesise that JMV2959 prevents morphine-
induced reward via stimulation of delta receptor active peptides in striatum and ventral
tegmental areas. In addition, hippocampal peptides that activate kappa receptor may be
involved in JMV2959's ability to regulate memory formation of reward. Given that development
of drug addiction depends, at least in part, of the effects of addictive drugs on the mesolimbico.2015.10.004
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Acute as well as chronic exposure of addictive drugs profoundly
inﬂuences the mesolimbic dopamine system, an important key
circuit of the brain reward systems (Nestler, 2005). These
effects have been proposed to underlie, at least in part,
development of drug addiction (Wise, 2004). Drug addiction
cause a wide range of harmful effects to the individual as well
as the society and novel pharmacological interventions, treating
this major public health problem, are warranted (Koob and Le
Moal, 2001). By clarifying the signalling systems mediating the
ability of addictive drugs to activate the mesolimbic dopamine
system, unique treatment strategies for substance use disorders
can be identiﬁed.
Research have shown that common neurobiological mechan-
isms regulate the intake of and reward induced by food and
addictive drugs (Morganstern et al., 2011), proposing that the
role of the food regulatory gut–brain peptides such as ghrelin
include reward mediation. Initially, it was shown that ghrelin
causes release of growth hormone (Kojima et al., 1999) and
induces adiposity in rats (Tschop et al., 2000). To date it is well
known that ghrelin increases food intake, hunger as well as
stimulates appetite via hypothalamic circuits (for review see
Egecioglu et al. (2011)). In addition to the hypothalamus,
ghrelin receptors (GHS-R1A) are expressed in reward related
areas such as the amygdala, striatum, prefrontal cortex,
ventral tegmental area (VTA) and hippocampus (for review
see Engel and Jerlhag (2014)) implying that the physiological
role of ghrelin extends beyond energy homoeostasis regula-
tion. Indeed, the orexigenic peptide ghrelin was shown to be
an activator of the mesolimbic dopamine system as well as a
regulator of reward, motivation and intake of alcohol, nico-
tine, amphetamine and cocaine in mice (for review see Engel
and Jerlhag (2014)).
Opioids, like other addictive drugs, activate the mesolimbic
dopamine system causing accumbal dopamine release via
activation of μ- and/or δ-opioid receptors in the nucleus
accumbens (NAc) (Hirose et al., 2005; Murakawa et al., 2004;
Yoshida et al., 1999) and in the VTA, presumably by decreasing
the GABA-inhibition of dopamine neurons (Johnson and North,
1992). Furthermore, accumbal κ-opioid receptors regulate the
activity of mesolimbic dopamine system (Chefer et al., 2005;
Spanagel et al., 1992). Repeated exposure to opioids produces
adaptive changes of several neurotransmitters, including opioid
peptides, in reward areas, which contribute to the develop-
ment of addiction (De Vries and Shippenberg, 2002). In rats
pharmacological suppression of the GHS-R1A attenuates
morphine-induced accumbal dopamine release as well as
stereotypic behaviours (Sustkova-Fiserova et al., 2014). The
aim of the ﬁrst part of the present series of experiments was to
investigate the acute effect of a GHS-R1A antagonist, JMV2959,
on the ability of morphine to cause a locomotor stimulation,
accumbal dopamine release and to conditioned placepreference in mice. The aim of the second part of this study
was to evaluate the effect of repeated JMV2959 or ghrelin
treatment on opioid peptide levels (Met-enkephalin-Arg6Phe7
(MEAP), dynorphin B (DynB) and Leu-enkephalin-Arg6 (LeuArg))
in reward related areas including the amygdala, striatum,
prefrontal cortex, VTA and hippocampus.
2. Experimental procedures
2.1. Animals
Adult post-pubertal age-matched male NMRI mice (8–12 weeks old
and 25–40 g body weight; Charles River, Sulzfeld, Germany) were
used. In brief, all mice were group housed and maintained at a 12/
12 h light/dark cycle (lights on at seven am). Tap water and food
(Normal chow; Harlan Teklad, Norfolk, England) were supplied ad
libitum, except during the experimental setups. New mice were
used for each single behavioural test as well as for the opioid
peptide analysis. The experiments were approved by the Swedish
Ethical Committee on Animal Research in Gothenburg. All efforts
were made to minimise animal suffering, and to reduce the number
of animals used. All animals were allowed to acclimatize at least
one week before the start of the experiments.
2.2. Drugs
Morphine hydrochloride (Apoteksbolaget Sahlgrenska Hospital; Gothen-
burg, Sweden) was dissolved in vehicle (0.9% sodium chloride solution)
and was administered i.p. at a dose of 20 mg/kg 10 min prior to
initiation of the experiment. This dose was selected since a lower dose
(10 mg/kg, i.p.) did not cause a locomotor stimulation in our mice (data
not shown). The selected dose (6 mg/kg, i.p.) of JMV2959 (synthesised
at the Institut des Biomolécules Max Mousseron (IBMM), UMR5247, CNRS,
Montpellier 1 and 2 Universities, France), a GHS-R1A antagonist, was
determined previously and has no effect on locomotor activity,
accumbal dopamine release and conditioned place preference in mice
(Jerlhag et al., 2009). JMV2959 was dissolved in vehicle (0.9% sodium
chloride solution) and was always administered twenty minutes prior to
morphine exposure or decapitation for analysis of opioid peptide levels.
The selected dose of JMV2959 did not affect the mice gross behaviour in
any experiment. For the behavioural tests JMV2959 was administered
acutely since our pervious studies show that a single injection of
JMV2959 attenuates drug induced reward (for review see Engel and
Jerlhag (2014)). JMV2959 was administered sub-chronically for ﬁve
subsequent days for the opioid peptide analysis to increase the
possibility to detect a robust effect. In addition, with repeated
injections you avoid the possible confounding effect of acute injection
stress on peptides. Acylated rat ghrelin (Bionuclear; Bromma, Sweden)
was diluted in 0.9% sodium chloride and the selected dose of ghrelin
(0.33 mg/kg, i.p.) has previously been shown to cause reward in mice
(Jerlhag, 2008). A balanced design was used for all drug challenges.
2.3. Locomotor activity experiments
Previous studies have shown that morphine causes a locomotor stimula-
tion in rodents (Wise and Bozarth, 1987). Locomotor activity was
J.A. Engel et al.2366registered in eight sound attenuated, ventilated and dim lit locomotor
boxes (420 420 200 mm, Kungsbacka mät- och reglerteknik AB;
Fjärås, Sweden). Five by ﬁve rows of photocell beams, at the ﬂoor
level of the box, creating photocell detection allowed a computer-based
system to register the activity of the mice. Locomotor activity was
deﬁned as the accumulated number of new photocell beams interrupted
during a 60-min period. In all experiments the mice were allowed to
habituate to the locomotor activity box one hour prior to drug
challenges. There were no differences between habituation in any of
the treatment groups (data not shown).
In the ﬁrst series of experiment the effects of JMV2959 (6 mg/kg,
i.p.) on morphine-induced (20 mg/kg, i.p.) locomotor stimulation
were investigated. JMV2959 was administered 20 min prior to
morphine and the activity registration started ten minutes after
the last injection. Each mouse received one treatment combination
(vehicle/vehicle, JMV2959/vehicle, morphine/vehicle or JMV2959/
morphine; n=8 per treatment combination) and was only subjected
to one experimental trial.
2.4. Conditioned place preference
To evaluate the effects of JMV2959 on the rewarding effects of morphine
in newmice, conditioned place preference tests were performed in mice
as previously described (Jerlhag, 2008). In brief, a two-chambered CPP
apparatus, with 45 lx illumination and distinct visual and tactile cues was
used. One compartment was deﬁned by black and white striped walls
and by a dark laminated ﬂoor whereas the other had a white painted
wooden ﬂoor and walls of wooden texture. The procedure consisted of
pre-conditioning (day 1), conditioning (days 2–5), and post-conditioning
(day 6). At preconditioning, mice were injected i.p. with vehicle and
was placed in the chamber with free access to both compartments
during 20 min to determine the initial place (or side) preference.
Conditioning (20 min per session) was done using a biased procedure in
which morphine (20 mg/kg) was paired with the least preferred
compartment and vehicle with the preferred compartment. All mice
received one injection of morphine as well as of vehicle every day and
the injections were altered between morning and afternoon in a
balances design. At post-conditioning the mice (n=16) were injected
with JMV2959 (6 mg/kg, i.p.) or an equal volume of vehicle solution and
20 min later placed on the midline between the two compartments with
free access to both compartments for 20 min (creating the following
treatment groups; Morph-Veh and Morph-JMV2959).
Condition place preference was calculated as the difference in %
of total time spent in the drug-paired (i.e. least preferred) compart-
ment during the post-conditioning and the pre-conditioning session.
2.5. In vivo microdialysis and dopamine release
measurements
Given that JMV2959 attenuates the morphine induced-locomotor
stimulation and conditioned place preference in mice, the effect of
JMV2959 (6 mg/kg, i.p.) on morphine-induced (20 mg/kg, i.p.) accum-
bal dopamine release was investigated using in vivo microdialysis in
freely moving mice. For measurements of extracellular dopamine
levels, mice were implanted unilaterally with a microdialysis probe
positioned in the nucleus accumbens. Therefore, the mice were
anaesthetised with isoﬂuran (Isoﬂuran Baxter; Univentor 400 Anaesthe-
sia Unit, Univentor Ldt., Zejtun, Malta), placed in a stereotaxic frame
(David Kopf Instruments; Tujunga, CA, USA) and kept on a heating pad
to prevent hypothermia. Xylocain adrenalin (5 μg/ml; Pﬁzer Inic; New
York, USA) was used as local anaesthetics and carprofen (Rimadyl,
5 mg/kg i.p.) (Astra Zeneca; Gothenburg, Sweden) was used to relieve
any possible pain. The skull bone was exposed and one hole for the
probe and one for the anchoring screw were drilled. The probe was
randomly alternated to either the left or right side of the brain. The
coordinates of 1.5 mm anterior to the bregma, 70.7 lateral to the
midline and 4.7 mm below the surface of the brain surface was used forthe nucleus accumbens (Franklin and Paxinos, 1997). The exposed tip of
the dialysis membrane (20,000 kDa cut off with an o.d./i.d. of 310/
220 μm, HOSPAL, Gambro, Lund, Sweden) of the probe was 1 mm. All
probes were surgically implanted two days prior to the experiment.
After surgery the mice were kept in individual cages until the test day
(Macrolon III).
On the test day the probe was connected to a microperfusion
pump (U-864 Syringe Pump; AgnThós AB) and perfused with Ringer
solution at a rate of 1.5 μl/min. After one hour of habituation to the
microdialysis set-up, perfusion samples were collected every
20 min. The baseline dopamine level was deﬁned as the average
of three consecutive samples before the ﬁrst drug/vehicle chal-
lenge, and the increase in accumbal dopamine was calculated as
the percent increase from baseline. After the baseline samples
(40 min until 0 min), mice were injected with JMV2959 or vehicle
(at 0 min), which was followed by a morphine or vehicle injection
(at 20 min). Following these drug administrations an additional
eight 20 min samples were collected. Collectively the following
treatment groups (n=8 in each group) were created: vehicle–
vehicle (Veh–Veh), vehicle–morphine (Veh–Morph), JMV2959-
vehicle (JMV2959-Veh) and JMV2959-morphine (JMV2959-Morph).
The dopamine levels in the dialysates were determined by HPLC with
electrochemical detection. A pump (Gyncotec P580A; Kovalent AB; V.
Frölunda, Sweden), an ion exchange column (2.0 100 mm, Prodigy
3 μm SA; Skandinaviska GeneTec AB; Kungsbacka, Sweden) and a
detector (Antec Decade; Antec Leyden; Zoeterwoude, The Netherlands)
equipped with a VT-03 ﬂow cell (Antec Leyden) were used. The mobile
phase (pH 5.6), consisting of sulphonic acid 10 mM, citric acid 200 mM,
sodium citrate 200 mM, 10% EDTA, 30% MeOH, was vacuum ﬁltered using
a 0.2 μm membrane ﬁlter (GH Polypro; PALL Gelman Laboratory; Lund,
Sweden). The mobile phase was delivered at a ﬂow rate of 0.2 ml/min
passing a degasser (Kovalent AB), and the analyte was oxidised at
+0.4 V.
After the microdialysis experiments were completed, the mice were
decapitated, and probes were perfused with pontamine sky blue 6BX to
facilitate probe localisation. The brains were mounted on a vibroslice
device (752 M Vibroslice; Campden Instruments Ltd., Loughborough, UK)
and cut in 50 μm sections. The location of the probe was determined by
gross observation using light microscopy. The exact position of the probe
was veriﬁed (Franklin and Paxinos, 1997) and only mice with correct
placements were used in the statistical analysis.
2.6. Treatment and dissection
The effects JMV2959 treatment on the levels of MEAP, DynB and
LeuArg in reward related areas were investigated. Mice were
injected with either JMV2959 (6 mg/kg, i.p., n=8) or an equal
volume of vehicle (i.p., n=8) for ﬁve subsequent days. 20 min
following the last injection the mice were sacriﬁced and the brains
from these mice were collected. Separate mice were injected with
either ghrelin (0.33 mg/kg, i.p., n=8) or an equal volume of vehicle
(i.p., n=8) for ﬁve subsequent days. Five minutes following the last
injection the mice were sacriﬁced and the brains from these mice
were collected. The amygdala, striatum, prefrontal cortex, VTA and
hippocampus were rapidly dissected and immediately put on dry ice
and then stored at 80 1C until further processing.
2.7. Opioid peptide levels analysis
The homogenisation and peptide extraction procedures followed a
standard procedure, previously described in detail (Nylander et al.,
1997). In short, hot (95 1C) acetic acid (1 M) was added to the
frozen samples. The samples were heated in a water bath (95 1C)
for 5 min, cooled on ice and then homogenised with a Branson
Soniﬁer (Danbury, CT, USA). The homogenate was reheated at 95 1C
for 5 min and cooled on ice before centrifugation for 15 min at 4 1C
and 12,074 g in a Beckman GS-15R centrifuge (Fullerton, CA,
2367Ghrelin and morphine rewardUSA). The extracts were further puriﬁed according to a previously
described procedure (Nylander et al., 1997). Two fractions were
collected: fraction III (Leu-Arg and MEAP) and fraction V (DynB).
The samples were dried in a vacuum centrifuge (Savant SpeedVac
Plus SC210A; Thermo Scientiﬁc Inc., Waltham, MA USA) and stored
in the freezer (20 1C) until peptide analysis.
The immunoreactive (ir) levels of DynB, LeuArg and MEAP were
analysed with well-established radioimmunoassays and the proto-
cols have been described in detail elsewhere (Nylander et al.,
1997). In the DynB assay, goat anti-rabbit IgG (GARGG; Bachem,
Bubendorf, Switzerland) was used to separate free and antibody-
bound peptide. The Dyn antiserum (113+) was used in a ﬁnal
dilution of 1:600000. The cross-reactivity with big Dyn was 100% and
with DynB (1–29) 1%. No cross-reactivity with other opioid peptides
was observed. In the LeuArg and MEAP assays, a charcoal suspension
was used to separate free and antibody-bound peptide. For the
LeuArg antiserum (91:6D+, ﬁnal dilution 1:60000), cross-reactivity
was less than 0.01% for Leu-enkephalin and MEAP, 0.02% for DynB,
0.04% for DynA, and 0.08% for alpha-neoendorphin. The MEAP
antiserum 90:3D (II) was used in a ﬁnal dilution of 1:160 000.
Cross-reactivity with Met-enkephalin, Met-enkephalin-Arg6, Met-
enkephalin-Arg6Gly7Leu8, Leu-enkephalin and Leu-enkephalin-Arg6
was o0.1%.2.8. Statistical analysis
Locomotor activity data was evaluated by a one-way ANOVA
followed by Bonferroni post-hoc tests. The condition place pre-
ference data were evaluated by an unpaired t-test. The micro-
dialysis experiments were evaluated by a two-way ANOVA followed
by Bonferroni post-hoc test for comparisons between different
treatments and speciﬁcally at given time points. The peptide levels
were analysed with an unpaired t-test. Data are presented as
mean7SEM. A probability value of Po0.05 was considered as
statistically signiﬁcant.3. Results
3.1. Effects of JMV2959 on morphine-induced
locomotor stimulation, accumbal dopamine release
and conditioned place preference in mice
An overall main effect of treatment was found on locomotor
activity in mice following systemic administration of mor-
phine (20 mg/kg) and JMV2959 (6 mg/kg) (F(3,27)=7.409,
P=0.0009; n=8 for Veh–Veh, JMV2959-Veh, JMV2959-Morph
and n=7 for Veh-Morph). As shown in Figure 1A, posthoc
analysis revealed that pre-treatment with a single injection
of JMV2959 (Po0.001) signiﬁcantly attenuated the mor-
phine induced locomotor stimulation (Po0.01 Veh–Veh vs
Veh–Morph). The selected dose of JMV2959 had no effect on
locomotor activity compared to vehicle treatment
(P40.05). There was no difference in locomotor activity
response in vehicle treated mice and JMV2959-morhpine
treated mice (P40.05).
The morphine-induced (20 mg/kg) (Morph–Veh) condi-
tioned place preference was signiﬁcantly attenuated by an
acute single injection of JMV2959 (6 mg/kg) (Morph-
JMV2959) on the post-conditioning day (P=0.025, n=8 in
each group; Figure 1B).
Accumbal microdialysis measurements of dopamine in mice
revealed an overall main effect of treatment (F(3,33)=24.15,
Po0.0001), time F(11,308)=7.05, Po0.0001) and treatmenttime interaction (F(11,308)=8.63, Po0.0001)(Figure 1C; n=8
in each group). Morphine increased accumbal dopamine release
relative to vehicle treatment at time interval 40–180 min
(Po0.001). As shown in Figure 1C this effect was reduced by
pre-treatment with JMV2959 at time interval 40–80 (Po0.01),
100 (Po0.001), 140 (Po0.01) and 160–180 min (Po0.001).
JMV2959 reduced, but did not completely block, morphine
induced accumbal dopamine release since there was a differ-
ence between vehicle treatment and JMV2959-morphine treat-
ment at time interval 60–80 (Po0.01), 100 (Po0.001), 140
(Po0.01) and 160 min (Po0.05). The selected dose of JMV2959
had no signiﬁcant effect on accumbal dopamine release
compared to vehicle treatment at any time interval (P40.05).
3.2. Effects of sub-chronic JMV2959 or ghrelin
treatment on opioid peptide levels
The immunoreactive (ir) levels of the three peptides in the
brain areas measured can be found in Tables 1 and 2. Sub-
chronic JMV2959 treatment signiﬁcantly increased the
levels of MEAP in the VTA, DynB in hippocampus and LeuArg
in striatum (Table 1). There were no differences in any
other areas investigated namely amygdala and prefrontal
cortex. Sub-chronic ghrelin treatment did not signiﬁcantly
alter the levels of MEAP, DynB or LeuArg (Table 2).
4. Discussion
The present study further supports the hypothesis that the
physiological role of the orexigenic peptide includes reward
regulation. Indeed, we showed that peripheral administra-
tion of a GHS-R1A antagonist attenuates the ability of
morphine to cause a locomotor stimulation, increase the
dopamine levels in NAc and to induce a conditioned place
preference in mice. We also found that sub-chronic
JMV2959, but not ghrelin, treatment increased the ir tissue
levels of MEAP in the VTA, DynB in hippocampus and LeuArg
in striatum, providing the ﬁrst evidence that the ability of
ghrelin signalling to regulate reinforcement may involve
opioid peptides.
The data presented herein show that GHS-R1A antagonism
affects the ability of morphine to activate the mesolimbic
dopamine system in mice. In accordance are the ﬁndings
showing that JMV2959 blocks the ability of morphine to
increase the extracellular levels of accumbal dopamine and
to cause a stereotyped behaviour in rats (Sustkova-Fiserova
et al., 2014). Supportively, central ghrelin administration
augments the breakpoint, but not the number of active lever
presses, in the progressive ratio reinforcement schedule in
rats self-administrating heroin, (Maric et al., 2012). The
contention that ghrelin signalling underlies drug addiction is
further supported by the ﬁndings showing that JMV2959
reduces the intake as well as the motivation to consume
alcohol in rats and that amphetamine, cocaine and nicotine
induced reward is blocked by the GHS-R1A antagonism in
rodents (for review see Engel and Jerlhag (2014)) and that
polymorphisms in ghrelin related genes are associated with
the intake of alcohol, smoking and amphetamine (for review
see Engel and Jerlhag (2014)).
The present ﬁndings with increased levels of opioid
peptides in the striatum, VTA and hippocampus after sub-
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Figure 1 The GHS-R1A antagonist JMV2959 attenuates morphine-induced locomotor stimulation, accumbal dopamine release and
conditioned place preference in mice. (A) Morphine-induced (20 mg/kg i.p.) locomotor stimulation was attenuated by a single
injection of JMV2959 (6 mg/kg i.p.) (n=7–8 in each group; **Po0.01, ***Po0.001 one-way ANOVA followed by a Bonferroni post-hoc
test). (B) The morphine-induced (20 mg/kg i.p.) condition place preference (CPP) was attenuated by an acute single injection of
JMV2959 (6 mg/kg i.p.) in mice (n=8 in each group, *Po0.05, unpaired t-test). (C) First we demonstrated a signiﬁcant effect of
morphine (20 mg/kg i.p.) to increase dopamine release in comparison to vehicle treatment (time interval 40–180 min (Po0.001),
Veh–Veh vs Veh–Morph). As shown in (C) pre-treatment with JMV2959 (6 mg/kg i.p.) attenuated the morphine-induced increase in
dopamine release compared to vehicle pre-treatment at time interval 40–100 and 140–180 min (Po0.01, Po0.001, JMV2959-Morph
compared to Veh–Morph treatment). The selected dose of JMV2959 had no signiﬁcant effect on accumbal dopamine release
compared to vehicle treatment at any time interval (P40.05, Veh–Veh vs JMV2959-Veh). JMV2959 reduced, but did not completely
block, the morphine induced accumbal dopamine release at time interval 60-140 (*Po0.05, **Po0.01, ***Po0.001, JMV2959-Morph
compared to Veh–Morph treatment). Arrows represent time points of injection of JMV2959, vehicle and morphine. Data analysed
with a Two-way ANOVA followed by a Bonferroni post-hoc test (n=8 in each group). Veh–veh (Square), Veh–Morph (rhomb), JMV2959-
Veh (Triangle), JMV2959-Morph (circle). All values represent mean7SEM.
J.A. Engel et al.2368chronic JMV2959 treatment suggest for the ﬁrst time
interactions between opioid peptides and ghrelin signalling.
The endogenous opioids are implicated in rewarding effects,
not only induced by opioids but also other drugs of abuse
and natural rewards, and in adaptive processes seen after
repeated drug exposure (Trigo et al., 2010; Van Ree et al.,
2000). Indeed the activity of the mesolimbic dopamine
system is regulated by endogenous opioids at both the level
of the VTA and the NAc (Hirose et al., 2005; Spanagel et al.,
1992) and the actions have been shown to be either direct
or indirect through modulation of other transmitters
(Charbogne et al., 2014).
We found herein that sub-chronic JMV2959 treatment
increased the levels of MEAP in the VTA. MEAP is exclusively
derived from proenkephalin and was used as a marker of
proenkephalin peptides that mainly activate δ-opioidreceptors. We hypothesise that the increased levels of
endogenous MEAP in the VTA following JMV2959 treatment
may prevent morphine’s ability to decrease the GABA-
inhibition of mesoaccumbal dopamine neurons (Johnson
and North, 1992), which may contribute to the reduced
morphine-induced effects seen following after JMV2959.
Supportively, GHS-R1A are located on GABAergic interneur-
ons in the VTA (Abizaid et al., 2006). Moreover, previous
studies have shown that intra-VTA infusion of JMV2959, via
unknown mechanisms, attenuates ghrelin-induced reward
(Jerlhag et al., 2011) as well as ghrelin-mediated sucrose
intake in rodents (Skibicka et al., 2011), suggest that
ventral tegmental GHS-R1A are important for reward reg-
ulation. In support for such a contention are the ﬁndings
showing that other hunger regulating peptides, such as
galanin and orexin, mediate the rewarding properties of
Table 1 Sub-chronic JMV2959 treatment signiﬁcantly
increased the ir levels of Met5-enkephalin-Arg6Phe7 (MEAP)
in the ventral tegmental area (VTA), the ir levels of
Dynorphin B (DynB) in hippocampus (HC) as well as the ir
levels of and Leu-enkephalin-Arg6 (LeuArg) in striatum
(STR) compared to vehicle treatment. There were no
differences in any other areas investigated. All values
represent mean7SEM. (amygdala (AMY), and prefrontal
cortex (PFC)).
JMV2959 Vehicle p-Value
Ir MEAP levels
AMY 14.5273.91 15.6174.37 0.838
STR 43.4775.54 47.6077.94 0.754
PFC 3.6170.90 2.9470.41 0.450
VTA 8.6970.75 4.6370.42 0.003
HC 4.5270.80 2.5670.23 0.170
Ir DynB levels
AMY 2.5670.41 1.9070.25 0.759
STR 8.6970.89 10.1770.91 0.547
PFC 2.2470.36 1.6070.20 0.169
VTA 8.8970.55 5.9870.21 0.079
HC 3.7070.41 2.3670.19 0.042
Ir LeuArg levels
AMY 13.4671.69 11.0771.45 0.270
STR 14.5070.89 12.1270.93 0.046
PFC 11.2171.32 10.8071.44 0.776
VTA 12.9671.63 10.9671.39 0.245
HC 5.2970.75 5.6770.72 0.663
Table 2 Sub-chronic ghrelin treatment did not alter the
ir levels of Met5-enkephalin-Arg6Phe7 (MEAP), dynorphin B
(DynB) or Leu-enkephalin-Arg6 (LeuArg) in any of the
reward related areas investigated, i.e. the ventral teg-
mental area (VTA), amygdala (AMY), striatum (STR), pre-
frontal cortex (PFC) and hippocampus (HC). All values
represent mean7SEM.
Ghrelin Vehicle p-Value
Ir MEAP levels
AMY 12.0073.91 15.4673.02 0.517
STR 43.5977.24 61.15712.46 0.176
PFC 3.7570.46 3.1770.64 0.550
VTA 11.9671.03 10.6070.91 0.249
HC 6.7571.88 5.2071.01 0.314
Ir DynB levels
AMY 3.9771.09 5.4272.27 0.488
STR 11.1570.89 13.0372.41 0.434
PFC 3.2370.50 2.3870.18 0.072
VTA 5.1170.15 8.2571.59 0.070
HC 4.3270.87 3.1970.29 0.095
Ir LeuArg levels
AMY 9.6771.53 9.4771.29 0.928
STR 8.6970.87 8.8770.44 0.875
PFC 4.6170.47 4.4770.39 0.921
VTA 8.3571.04 6.9970.42 0.407
HC 4.9770.50 3.4770.41 0.086
2369Ghrelin and morphine rewardmorphine via local mechanisms within the VTA (Narita
et al., 2006; Richardson and Aston-Jones, 2012).
In the striatum, we found that sub-chronic JMV2959
increased the ir levels of LeuArg, suggesting that the ability
of JMV2959 to attenuate morphine-induced conditioned
place preference, dopamine release and locomotor stimula-
tion depends, at least in part, on enhanced accumbal δ-
opioid receptor activity. Increased LeuArg levels may result
from increased enzymatic conversion of dynorphin peptides
to enkephalins or from enhanced Dyn release in the NAc as a
response to increased dopamine, followed by degradation
into LeuArg. Albeit previous studies have shown that the
activity of the mesolimbic dopamine system is regulated via
κ-opioid receptors in the NAc (Spanagel et al., 1992) and
endogenous κ-opioid receptors provide a tonic inhibition of
mesoaccumbal dopamine neurotransmission and attenuates
cocaine induced release of dopamine in NAc (Chefer et al.,
2005), we did not show that JMV2959 alters the ir DynB
levels in the striatum. Therefore, further studies are
warranted on prodynorphin peptides to elucidate the inter-
actions between GHS-R1A antagonism and dynorphins.
In the present study we also showed that JMV2959 treatment
signiﬁcantly increases the levels of hippocampal DynB. Ghrelin
increases memory consolidation as well as dendritic spine
formation, generates long-term potentiation and induces mem-
ory facilitation via hippocampal GHS-R1A in rodents (Carlini
et al., 2010; Diano et al., 2006). Moreover, GHS-R1A knockout
mice display an improved spatial memory in the Morris water
maze test and a disrupted contextual memory in the fear-
conditioning paradigm compared to wild type mice (Albarran-
Zeckler et al., 2012). Dynorphin peptides, including DynB, are
abundant in hippocampus and they attenuate long term-
potentiation (Chavkin et al., 1985; Wagner et al., 1993) as well
as impair spatial learning in rats (Sandin et al., 1998). We
therefore hypothesise that the GHR-R1A antagonist may attenu-
ate memory of reward by inhibiting hippocampal long-term
potentiation via activation of DynB. Collectively, these data
provide novel potential mechanism by which JMV2959 via
opioid peptides may alter reinforcement. However, opioid
receptors are widely distributed in the brain, suggesting that
other areas, not included in the present study, may be involved
in GHS-R1A regulated morphine-induced reward. For example,
ghrelin-induced food intake as well as lever pressing for sucrose
is reduced by central or intra-hypothalamic administration of a
κ-opioid receptor antagonist (Romero-Pico et al., 2013). How-
ever, the role of opioid peptides in other areas needs to be
elucidated in upcoming studies.
The endogenous μ-receptor ligands, endomorphins and
beta-endorphin, were not analysed herein so we cannot rule
out a possible effect of JMV2959 on these peptides. Indeed,
the rewarding properties of morphine involve μ-opioid
receptors in the VTA as well as NAc (Hirose et al., 2005;
Johnson and North, 1992; Murakawa et al., 2004; Yoshida
et al., 1999). However, a μ-receptor antagonist does not
attenuated ghrelin-induced food intake (Naleid et al., 2005)
nor ghrelin-induced locomotor stimulation and accumbal
dopamine release (Jerlhag et al., 2011), implying that the
ability of the GHSR-1A antagonist to regulate reinforcement
does not include μ-receptors. On the other hand, JMV2959
did affect opioid peptides derived from proenkephalin and
prodynorphin showing that they may be involved in the
effects induced by GHSR-1A antagonists.
J.A. Engel et al.2370While previous studies have shown that systemic ghrelin
administration causes reward (Jerlhag, 2008) as well as
enhances the rewarding properties of addictive drugs (for
review see Engel and Jerlhag (2014)), we here show that sub-
chronic ghrelin treatment did not alter the ir tissue levels of
opioids peptides in any of the studied reward related areas.
Systemic ghrelin administration actives c-fos expression in
hypothalamic areas, but not in mesolimbic and hippocampal
areas (Pirnik et al., 2011) and the binding of ﬂuorescently
labelled ghrelin is limited to food regulatory neurons of the
hypothalamus (Schaeffer et al., 2013). Taken together with
the ﬁndings showing that ghrelin, exept from trace amounts
of in the hypothalamus, cannot be detected in deeper brain
areas following peripheral ghrelin administration (Furness
et al., 2011; Grouselle et al., 2008; Sakata et al., 2009),
raises the possibility that systemic ghrelin activates the
reward system via indirect mechanisms independent of
endogenous opioids. Supportively, ghrelin-induced accumbal
dopamine release requires upstream orexigenic hypothalamic
signalling (Cone et al., 2014), peripheral ghrelin administra-
tion does not alter alcohol intake in mice (Lyons et al., 2008)
and that neutralization of peripheral ghrelin does not
attenuate alcohol-induced reward in mice or alcohol intake
in rats (Jerlhag et al., in press). The possibility that sub-
chronic administration of ghrelin increases the ir tissue levels
of opioids peptides should be considered however this needs
to be investigated in detail in upcoming studies.
The ability of addictive drugs to cause stimulation, dopa-
mine release and to induce a conditioned place preference are
intimately associated with the reinforcing properties of addic-
tive drugs and these parameters are considered to constitute a
part of the addiction process (Wise, 2004). Given that we here
found that JMV2959 attenuates these reward parameters in
mice we hypothesise that GHS-R1A may play an important role
in addiction processes, and that endogenous opioids are
involved in these processes. Collectively these data indicate
that GHS-R1A antagonists should be elucidated as treatment
of drug dependence.Author disclosure
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